CORT-108297 is under clinical development by Corcept Therapeutics and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase II drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CORT-108297 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CORT-108297 overview
CORT-108297 is under development for the treatment of Alzheimer's disease and
Post-traumatic stress disorder. The drug candidate is administered by oral route. CORT 108297 is a next-generation product acts by targeting selective cortisol receptor (GR-II). It is a fused-ring azadecalin that blocks the glucocorticoid receptor II (GR-II) or cortisol receptor and reduces the receptor's activation by cortisol.
See Also:
Corcept Therapeutics overview
Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder among others. Corcept is headquartered in Menlo Park, California, the US.
For a complete picture of CORT-108297’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.